Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells.

Singer II, Scott S, Kawka DW, Chin J, Daugherty BL, DeMartino JA, DiSalvo J, Gould SL, Lineberger JE, Malkowitz L, Miller MD, Mitnaul L, Siciliano SJ, Staruch MJ, Williams HR, Zweerink HJ, Springer MS.

J Virol. 2001 Apr;75(8):3779-90.

2.

Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.

Brander C, Yang OO, Jones NG, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay C, Buchbinder S, Bergmann CC, Zweerink HJ, Wolinsky S, Blattner WA, Kalams SA, Walker BD.

J Virol. 1999 Dec;73(12):10191-8.

4.

Mutation of the alpha 2 domain disulfide bridge of the class I molecule HLA-A*0201. Effect on maturation and peptide presentation.

Warburton RJ, Matsui M, Rowland-Jones SL, Gammon MC, Katzenstein GE, Wei T, Edidin M, Zweerink HJ, McMichael AJ, Frelinger JA.

Hum Immunol. 1994 Apr;39(4):261-71.

PMID:
8071101
5.

Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells.

Zweerink HJ, Gammon MC, Utz U, Sauma SY, Harrer T, Hawkins JC, Johnson RP, Sirotina A, Hermes JD, Walker BD, et al.

J Immunol. 1993 Mar 1;150(5):1763-71.

PMID:
7679694
6.

Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.

Parker KC, Bednarek MA, Hull LK, Utz U, Cunningham B, Zweerink HJ, Biddison WE, Coligan JE.

J Immunol. 1992 Dec 1;149(11):3580-7.

PMID:
1331239
7.

Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonist.

Gammon MC, Bednarek MA, Biddison WE, Bondy SS, Hermes JD, Mark GE, Williamson AR, Zweerink HJ.

J Immunol. 1992 Jan 1;148(1):7-12.

PMID:
1727876
8.

The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2.

Bednarek MA, Sauma SY, Gammon MC, Porter G, Tamhankar S, Williamson AR, Zweerink HJ.

J Immunol. 1991 Dec 15;147(12):4047-53.

PMID:
1721637
9.

Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes.

Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR, Zweerink HJ.

J Immunol Methods. 1991 May 17;139(1):41-7.

PMID:
1904085
10.

Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity.

Poe M, Blake JT, Boulton DA, Gammon M, Sigal NH, Wu JK, Zweerink HJ.

J Biol Chem. 1991 Jan 5;266(1):98-103.

12.

A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia.

Zweerink HJ, Detolla LJ, Gammon MC, Hutchison CF, Puckett JM, Sigal NH.

J Infect Dis. 1990 Jul;162(1):254-7.

PMID:
2113078
13.

Glycolipids as host resistance stimulators.

Ponpipom MM, Hagmann WK, O'Grady LA, Jackson JJ, Wood DD, Zweerink HJ.

J Med Chem. 1990 Feb;33(2):861-7.

PMID:
2299649
14.

Steroidal glycolipid, L-644,257, is a potent enhancer of nonspecific host resistance.

Hagmann WK, Ponpipom MM, Jackson JJ, Wood DD, Boltz RC Jr, Zweerink HJ.

Int J Immunopharmacol. 1990;12(2):241-6.

PMID:
2329016
16.

Human cytotoxic lymphocyte tryptase. Its purification from granules and the characterization of inhibitor and substrate specificity.

Poe M, Bennett CD, Biddison WE, Blake JT, Norton GP, Rodkey JA, Sigal NH, Turner RV, Wu JK, Zweerink HJ.

J Biol Chem. 1988 Sep 15;263(26):13215-22.

17.

Suppression of in vitro granulocytopoiesis by captopril and penicillamine.

Hammond WP, Miller JE, Starkebaum G, Zweerink HJ, Rosenthal AS, Dale DC.

Exp Hematol. 1988 Sep;16(8):674-80.

PMID:
2841147
18.

Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Zweerink HJ, Gammon MC, Hutchison CF, Jackson JJ, Lombardo D, Miner KM, Puckett JM, Sewell TJ, Sigal NH.

Infect Immun. 1988 Aug;56(8):1873-9.

19.

X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa.

Zweerink HJ, Gammon MC, Hutchison CF, Jackson JJ, Pier GB, Puckett JM, Sewell TJ, Sigal NH.

Infect Immun. 1988 May;56(5):1209-14.

20.

Primary muscle disease: definition of a 25-kDa polypeptide myopathic specific chagas antigen.

Santos-Buch CA, Acosta AM, Zweerink HJ, Sadigursky M, Andersen OF, von Kreuter BF, Brodskyn CI, Sadigursky C, Cody RJ.

Clin Immunol Immunopathol. 1985 Dec;37(3):334-50.

PMID:
2414045
21.

In vivo and in vitro inhibition of human histidine decarboxylase by (S)-alpha-fluoromethylhistidine.

Tung AS, Blake JT, Roman IJ, Vlasses PH, Ferguson RK, Zweerink HJ.

Biochem Pharmacol. 1985 Oct 1;34(19):3509-15.

PMID:
4052095
22.

Parasite specific antibodies in three strains of mice after infection with Trypanosoma cruzi.

Zweerink HJ, Anderson OF, Greenblatt HC, Murray PK.

J Parasitol. 1985 Feb;71(1):43-9.

PMID:
3920376
23.
24.

The development of sensitive and specific radioimmunoassays for leukotrienes.

Rokach J, Hayes EC, Girard Y, Lombardo DL, Maycock AL, Rosenthal AS, Young RN, Zamboni R, Zweerink HJ.

Prostaglandins Leukot Med. 1984 Jan;13(1):21-5.

PMID:
6324239
25.

Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay.

Hayes EC, Lombardo DL, Girard Y, Maycock AL, Rokach J, Rosenthal AS, Young RN, Egan RW, Zweerink HJ.

J Immunol. 1983 Jul;131(1):429-33.

PMID:
6190920
26.
27.

Restriction endonuclease analysis of the DNA from varicella-zoster virus: stability of the DNA after passage in vitro.

Zweerink HJ, Morton DH, Stanton LW, Neff BJ.

J Gen Virol. 1981 Jul;55(Pt 1):207-11.

PMID:
6271904
29.

Cells infected with a cell-associated subacute sclerosing panencephalitis virus do not express M protein.

Machamer CE, Hayes EC, Zweerink HJ.

Virology. 1981 Jan 30;108(2):515-20. No abstract available.

PMID:
7467128
31.
32.

Antibodies against the measles matrix polypeptide after clinical infection and vaccination.

Machamer CE, Hayes EC, Gollobin SD, Westfall LK, Zweerink HJ.

Infect Immun. 1980 Mar;27(3):817-25.

33.

Measles-specific antibodies in sera and cerebrospinal fluids of patients with multiple sclerosis.

Hayes EC, Gollobin SD, Machamer CE, Westfall LK, Zweerink HJ.

Infect Immun. 1980 Mar;27(3):1033-7.

34.
35.

Measles virus nucleocapsids: large-scale purification and use in radioimmunoassays.

Moore PM, Hayes EC, Miller SE, Wright LL, Machamer CE, Zweerink HJ.

Infect Immun. 1978 Jun;20(3):842-6.

36.

HLA restriction of cell-mediated lysis of influenza virus-infected human cells.

McMichael AJ, Ting A, Zweerink HJ, Askonas BA.

Nature. 1977 Dec 8;270(5637):524-6. No abstract available.

PMID:
593371
37.

Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity.

Zweerink HJ, Askonas BA, Millican D, Courtneidge SA, Skehel JJ.

Eur J Immunol. 1977 Sep;7(9):630-5. No abstract available.

PMID:
303568
38.

Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses.

Zweerink HJ, Courtneidge SA, Skehel JJ, Crumpton MJ, Askonas BA.

Nature. 1977 May 26;267(5609):354-6. No abstract available.

PMID:
194164
39.

Characterization of the double-stranded RNA in replicase particles in reovirus-infected cells.

Morgan EM, Zweerink HJ.

Virology. 1977 Mar;77(1):421-3. No abstract available.

PMID:
841868
40.

Reovirus morphogenesis: characterization of subviral particles in infected cells.

Zweerink HJ, Morgan EM, Skyler JS.

Virology. 1976 Sep;73(2):442-53. No abstract available.

PMID:
960572
41.

Studies on the structure of reovirus cores: selective removal of polypeptide lambda 2.

White CK, Zweerink HJ.

Virology. 1976 Mar;70(1):171-80. No abstract available.

PMID:
3879
42.

Characterization of transcriptase and replicase particles isolated from reovirus-infected cells.

Morgan EM, Zweerink HJ.

Virology. 1975 Dec;68(2):455-66. No abstract available.

PMID:
1198927
43.
44.

Multiple forms of SS leads to DS RNA polymerase activity in reovirus-infected cells.

Zweerink HJ.

Nature. 1974 Feb 1;247(5439):313-5. No abstract available.

PMID:
4818368
45.

Studies on the topography of reovirus and bluetongue virus capsid proteins.

Martin SA, Pett DM, Zweerink HJ.

J Virol. 1973 Jul;12(1):194-8.

46.

Synthesis of reovirus double-stranded RNA within virionlike particles.

Zweerink HJ, Ito Y, Matsuhisa T.

Virology. 1972 Nov;50(2):349-58. No abstract available.

PMID:
4673850
47.

Isolation and characterization of two types of bluetongue virus particles.

Martin SA, Zweerink HJ.

Virology. 1972 Nov;50(2):495-506. No abstract available.

PMID:
4344192
48.

An ultrastructural study of virions and cores of reovirus type 3.

Luftig RB, Kilham SS, Hay AJ, Zweerink HJ, Joklik WK.

Virology. 1972 Apr;48(1):170-81. No abstract available.

PMID:
4111673
49.

Fate of parental reovirus in infected cell.

Chang CT, Zweerink HJ.

Virology. 1971 Dec;46(3):544-55. No abstract available.

PMID:
5167655
50.

Essential and nonessential noncapsid reovirus proteins.

Zweerink HJ, McDowell MJ, Joklik WK.

Virology. 1971 Sep;45(3):716-23. No abstract available.

PMID:
5166483

Supplemental Content

Loading ...
Support Center